 

#  BPDA Event: Industry Career Chat with Flare Therapeutic 

 





September 10, 2021

 

 

 ![Flare](/sites/g/files/omnuum8971/files/hmpa/files/flare_therapeutics_poster.jpg)

 

 The BPDA is hosting the next Industry Career Chat on September 30, from 4-5 pm with Jenny Mertz, Ph.D, Senior Director, Biology, and Robert Sims, Ph.D., CSO and co-founder of Flare Therapeutics. This is a great opportunity for intimate networking between postdocs steering towards industry positions and scientists/hiring managers at biotech, pharma and startup companies in Boston and Cambridge. Places are limited to 20 participants. Make sure to register here:

 <https://www.eventbrite.com/e/168967854401>

 *Jenny’s Flare characteristics: Moving programs forward with data-driven decisions and having fun doing it!*

 Jenny has experience ranging from early target discovery, to supporting phase 3 clinical development in small molecule oncology therapeutics, while working in discovery biology and leading translational biology over the past 12+ years. Over this time, Jenny has moved various projects forward with rigor and objectiveness, working on cross-functional teams to build strong data packages to give the best chance for success, from early target discovery to translationally focused efforts.

 *Robert’s Flare characteristics: Fostering communication and collaboration while having a blast.*

 With 20+ years of experience in the transcription field, including 10+ years in the drug discovery of gene control, Robert is passionate about working with diverse and talented teams to discover and develop novel transcription factor medicines. As a founding scientist of Constellation Pharmaceuticals, he feels fortunate to have experienced and contributed to nearly all aspects of company creation— from concept to becoming a public company, with multiple programs in clinical development. While at Constellation, Robert led the discovery and translational efforts for Pelabresib, a BET bromodomain inhibitor now in phase 3 clinical development for the treatment of myelofibrosis.



 

 

 



 

 

 Share on:- [     Facebook ](#)
- [     Twitter ](#)
- [     Linkedin ](#)